Regulatory effect of caffeic acid phenethyl ester on type I
collagen and interferon-gamma in bleomycin-induced pulmonary fibrosis in rat
Res Pharm Sci, 2013 Oct;8(4):243-252
Idiopathic pulmonary fibrosis (IPF) is a chronic lung
disease of unknown etiology. Recent investigations have demonstrated that the
impaired immune response is a common characteristic feature of IPF.
Unfortunately, no definitive and effective drug treatment is available that
could improve or at least inhibit the progressive course of this fatal disease.
That is why one of the main priorities of pulmonary fibrosis investigations is
to identify novel and effective molecular targets for preventive and
therapeutic interventions. caffeic acid phenethyl ester (CAPE) is one of the
most interesting bioactive compounds extracted from bee propolis. It has been
shown that CAPE has an antioxidant activity and modulatory impact on immune
system. Accordingly, the aim of the present study was to investigate the
regulatory effects of CAPE on the levels of type I collagen (COL-1) and
Interferon-gamma (IFN-γ) in bleomycin (BLM)-induced pulmonary fibrosis. Immunohistochemistry
procedure was employed to assess the effects of CAPE on lung tissue.
In this study, male Sprague-Dawley rats were divided into 5
groups (n=8) included 1: Positive control group: bleomycin (BLM). 2: Negative
(saline) control group. 3, 4: Treatment groups of 1 and 2: BLM+CAPE (5 and 10
μmol/kg/day, respectively). (5: Sham group: CAPE (10 μmol/kg/day). BLM
application resulted in significant changes in the level of studied parameters
as compared to the controls. CAPE could decrease type I collagen concentration,
modulate IFN-γ level, increase the animals' body weight and decrease the lung
index dose-dependently, compared with model group.
In conclusion, CAPE may provide a novel therapeutic target
for treating pulmonary fibrosis.
No comments:
Post a Comment